文献速递心外重症与机械循环支持

在拉丁美洲构建机械循环支持的公平可及:墨西哥首例Impella 5.5 p-VAD应用反思

Building Equitable Access to Mechanical Circulatory Support in Latin America: Reflecting on the Accomplishment of Utilizing the First Impella 5.5 p-VAD in Mexico.
PubMed 文献 · J Heart Lung Transplant · 2026-10-02

机械循环支持(MCS)改变了晚期心力衰竭和心源性休克的治疗,但不同医疗体系间可及性极不平等。墨西哥监管批准后,本研究机构在拉丁美洲首次为一位接受高风险Bentall手术的患者植入Impella 5.5。预防性临时MCS使血流动力学稳定、终末器官功能恢复、药物治疗优化、活动与康复得以实现。6个月随访时患者NYHA I级,左心室射血分数(LVEF)从30%恢复至56%。该经验还揭示了拉丁美洲扩大MCS的四大障碍:监管延迟、财务限制、多学科心衰与心源性休克项目的需求以及区域特异性证据的缺乏。

要点

  • 拉丁美洲首例Impella 5.5 p-VAD用于高风险Bentall手术的预防性临时MCS。
  • 6个月随访患者NYHA I级,LVEF从30%恢复至56%。
  • 扩大MCS面临监管延迟、财务限制、多学科项目需求和区域证据缺乏四大障碍。

核心结论

  • 该经验不仅是技术里程碑,更应成为推动拉丁美洲及其他资源受限医疗体系可持续、公平获得晚期心衰治疗的催化剂。

研究设计与样本

  • 本文为单例经验总结与反思性论述,报告了墨西哥首例Impella 5.5植入的临床过程及区域推广障碍。

主要发现

  • 预防性临时MCS使高风险Bentall手术患者血流动力学稳定、终末器官功能恢复、药物治疗优化、活动与康复得以实现。
  • 6个月随访时患者NYHA I级,LVEF从30%恢复至56%。

临床怎么用

  • 在高风险心脏手术中可考虑预防性使用临时MCS以稳定血流动力学并支持终末器官功能恢复。
  • 推动MCS发展需建立多学科心衰与心源性休克项目并协调国际行动以应对监管、财务和证据障碍。

局限性

  • 本文为单例经验报告,区域特异性证据稀缺,结论外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Mechanical circulatory support (MCS) has transformed the management of advanced heart failure (HF) and cardiogenic shock (CS), yet access remains profoundly unequal across healthcare systems. Following regulatory approval in Mexico, our institution performed the first Impella 5.5 implantation in Latin America in a patient undergoing high-risk Bentall surgery. Pre-emptive temporary MCS (t-MCS) enabled hemodynamic stabilization, recovery of end-organ function, optimization of medical therapy, mobilization, and rehabilitation. At 6-month follow-up the patient was in NYHA class I with recovery of left ventricular ejection fraction (LVEF) from 30% to 56%. Beyond the clinical outcome, this experience highlights both what is possible and four major barriers to expanding MCS in Latin America: regulatory delays, financial constraints, the need for multidisciplinary HF and CS programs, and the scarcity of region-specific evidence. Addressing these disparities will require coordinated international action, including a consortium focused on global advanced HF inequity, multinational data platforms, exchange of cost-effective regional solutions, and streamlined regulatory pathways for validated technologies. This experience should therefore serve not merely as a technological milestone, but as a catalyst for sustainable and equitable access to advanced HF therapies across Latin America and other resource-constrained healthcare systems.

来源:J Heart Lung Transplant,查看原文。版权归原作者所有。

引用

  1. Castillo-Perez M, Jimenez-Franco V, Jerjes-Sanchez C, et al. Building Equitable Access to Mechanical Circulatory Support in Latin America: Reflecting on the Accomplishment of Utilizing the First Impella 5.5 p-VAD in Mexico. J Heart Lung Transplant. 2026. PMID: 42826811. doi:10.1016/j.healun.2026.09.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。